Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CELC vs ZBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZBIO Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 3–3 Matrix Metrics)

ZBIO Overall Winner 6-Pillar Tally: CELC 2 – 2 ZBIO (2 Tie) Matrix Metrics: CELC 3 – 3 ZBIO

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over Celcuity Inc. (CELC) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). CELC carries a Unified Composite Score of 39.7/100 (SELL) at $60.57 (N/M Forward P/E, 0.0% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin).

  • Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. CELC 39.7/100 SELL) and 1.16β · 59% Vol risk profile, whereas CELC leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CELC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.5); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CELC vs ZBIO
CELC NASDAQ
Celcuity Inc. Common Stock
Services-Medical Laboratories
$60.57
-5.9% 1D
Market Cap $3.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.28β · 59% Vol
Unified Composite Score
39.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 59.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.7%), weak momentum, RSI 38
RSI-14: 38.5 · SMA20: $66.12 · SMA50: $71.78
ZBIO NASDAQ Head-to-Head Winner
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48

6-Pillar Scorecard Institutional Category Breakdown (CELC 2 – 2 ZBIO)

Columns: Metric · CELC · ZBIO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CELC
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $3.1B $1.9B
3. Profitability & Quality CELC
Gross Margin N/A N/A
Operating Margin 0.0% -2747.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1192.9% -265.1%
4. Balance Sheet & Cash Flow ZBIO
Cash Generation (TTM) -$264M -$273M
Cash Flow Margin N/A N/A
Net Cash / Leverage $577M Net Debt $177M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 84.0% (60th %ile) 103.9% (13th %ile)
Put/Call OI Skew 0.41x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CELC (3) vs ZBIO (3)
Institutional Metric CELC ZBIO Criterion Row Edge
Market Capitalization
Scale
$3.1B $1.9B Larger Scale CELC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth CELC
Operating Margin (TTM)
Profitability
0.0% -2747.5% Higher Margin CELC
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1192.9% -265.1% Higher ROE ZBIO
52-Week Range Position
Momentum
7% ($54–$151) 46% ($14–$45) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
1.28β · 59% Vol 1.16β · 59% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
39.7 / 100 (SELL) 49.4 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$264M ($577M Net Debt) -$273M ($177M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +5.39 pp
CELC: +7.05% · ZBIO: +12.44%
3M Horizon ZBIO +22.57 pp
CELC: -35.04% · ZBIO: -12.47%
6M Horizon ZBIO +119.35 pp
CELC: -54.18% · ZBIO: +65.17%
1Y Horizon ZBIO +7.89 pp
CELC: -29.57% · ZBIO: -21.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELC vs ZBIO. Trailing 12-month operating profitability (CELC 0.0% vs ZBIO -2747.5%) and valuation multiples (CELC N/M vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CELC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-1192.9% · N/M
ZBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-2747.5%
ROE / Fwd P/E-265.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CELC BREAKDOWN
136d in phase · OBV DISTRIBUTION
Current IV 84.0%
IV Percentile 60th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CELC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 103.9%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CELC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CELC vs ZBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over Celcuity Inc. (CELC) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). CELC carries a Unified Composite Score of 39.7/100 (SELL) at $60.57 (N/M Forward P/E, 0.0% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin). Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. CELC 39.7/100 SELL) and 1.16β · 59% Vol risk profile, whereas CELC leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CELC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.5); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CELC leads the Growth & Scale pillar: CELC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ZBIO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin). On trailing 12-month operating scale, CELC generates N/A in USD-normalized revenue versus $11M for ZBIO. In operating R&D and SG&A reinvestment, CELC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZBIO.

CELC and ZBIO trade at balanced relative valuation multiples. CELC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELC (-1192.9% ROE) versus ZBIO (-265.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CELC carries 84.0% implied volatility (60th %ile, Balanced (25th–60th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.28β · 59% Vol realized risk). By comparison, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.